Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative intravenous iron as a blood-sparing strategy in orthopedic surgery
NL-OMON22057Phase 4Active, not recruiting
- Sponsor
- Albert Schweitzer Hospital
- Start
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Iron and erythropoietin in iron deficiency anemia (IDA) and anaemia (2 arms), sponsored by Albert Schweitzer Hospital. Primary endpoints: Reduction in erythropoietin requirement and Reduction in allogeneic blood transfusions. Started Oct 2013; status: active, not recruiting.
02
Drugs
Ironerythropoietin
03
Conditions
iron deficiency anemia (IDA)anaemia
Beyond the preview
Go deeper on NL-OMON22057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22057.